NCT03401788: An ongoing trial by Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
This trial is ongoing. It must report results 1 year, 3 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03401788 |
|---|---|
| Title | An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 2, 2018 |
| Completion date | March 29, 2026 |
| Required reporting date | March 29, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |